La Iniciativa de Medicamentos Innovadores IMI2 abrió el pasado 30 de noviembre la 13ª convocatoria formada por los 13 topics siguientes:
- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- ConcePTION – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Pilot programme on a clinical compound bank for repurposing – this programme contains four topics on cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; and rare/orphan diseases
Son propuestas a evaluar en 2 fases, siendo el plazo de cierre de la 1ª fase el 28 de febrero de 2018 a las 17.00 h (hora de Bruselas). El presupuesto para esta convocatoria es de 223.053.000 Euros.
Más información en el siguiente enlace: IMI launches new calls for proposals
